| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DHRS2 |
| Uniprot No | Q13268 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-300aa |
| 氨基酸序列 | MLSAVARGYQGWFHPCARLSVRMSSTGIDRKGVLANRVAVVTGSTSGIGFAIARRLARDGAHVVISSRKQQNVDRAMAKLQGEGLSVAGIVCHVGKAEDREQLVAKALEHCGGVDFLVCSAGVNPLVGSTLGTSEQIWDKILSVNVKSPALLLSQLLPYMENRRGAVILVSSIAAYNPVVALGVYNVSKTALLGLTRTLALELAPKDIRVNCVVPGIIKTDFSKVVRIGFMGMSLSGRTSRNIISCRGLGSQRTVQESCPSCALQMPATSTGRTLRWQATPLGSERSGGGCVAVVPGPGA |
| 预测分子量 | 58.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DHRS2重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**：*"Expression, purification and enzymatic characterization of human DHRS2 in Escherichia coli"*
**作者**：Zhang Y, Wang L, Chen X, et al.
**摘要**：该研究报道了人源DHRS2基因在大肠杆菌中的重组表达与纯化，并验证了其作为短链脱氢酶/还原酶(SDR家族)的催化活性。通过体外酶动力学实验，证实重组DHRS2对多种底物(如视黄醇衍生物)具有还原酶活性，为后续功能研究奠定基础。
---
2. **文献名称**：*"Structural insights into DHRS2-mediated substrate recognition in retinol metabolism"*
**作者**：Li H, Liu T, Zhou R, et al.
**摘要**：作者通过X射线晶体学解析了重组DHRS2蛋白的三维结构，揭示了其底物结合口袋的关键氨基酸残基。研究提出DHRS2通过特异性识别视黄醇类化合物参与维生素A代谢调控，为开发靶向DHRS2的代谢疾病药物提供结构依据。
---
3. **文献名称**：*"DHRS2 suppresses hepatocellular carcinoma growth by interacting with PTEN and regulating AKT signaling"*
**作者**：Xu M, Jiang Y, Wang H, et al.
**摘要**：该研究发现DHRS2在肝癌组织中表达下调，并通过重组蛋白实验证明DHRS2与PTEN蛋白相互作用，抑制AKT信号通路活化。体外实验表明，过表达重组DHRS2可显著抑制肝癌细胞增殖，提示其作为肿瘤抑制因子的潜在机制。
---
以上文献涵盖了DHRS2重组蛋白的表达纯化、结构功能及疾病机制研究。如需具体DOI或发表年份，可进一步补充检索条件。
**Background of DHRS2 Recombinant Protein**
DHRS2 (Dehydrogenase/Reductase Member 2), also known as retinol dehydrogenase 12 (RDH12), is a member of the short-chain dehydrogenase/reductase (SDR) superfamily. This protein is encoded by the *DHRS2* gene in humans and is localized to the endoplasmic reticulum and mitochondria. It plays a regulatory role in cellular processes, including retinol metabolism, oxidative stress response, and cell differentiation. Structurally, DHRS2 contains conserved motifs typical of SDR enzymes, such as the NAD(P)+-binding Rossmann fold and catalytic tetrad, enabling its enzymatic activity in redox reactions.
Studies suggest DHRS2 is involved in modulating retinoic acid (RA) signaling by converting retinol to retinaldehyde, a rate-limiting step in RA synthesis. RA, a critical signaling molecule, regulates gene expression, cellular growth, and apoptosis. Dysregulation of DHRS2 has been linked to pathological conditions, including cancer. For instance, DHRS2 is frequently downregulated in hepatocellular carcinoma (HCC) and colorectal cancer, where its loss correlates with tumor progression and poor prognosis. Its tumor-suppressive role is attributed to its ability to enhance RA signaling, promote apoptosis, and inhibit epithelial-mesenchymal transition (EMT).
Recombinant DHRS2 protein is engineered for in vitro studies to elucidate its biochemical properties, substrate specificity, and interactions with cofactors like NAD+/NADP+. It is produced using expression systems (e.g., *E. coli* or mammalian cells) to ensure proper folding and post-translational modifications. Applications include enzyme activity assays, structural studies, and screening for potential therapeutic agents targeting RA metabolism or cancer pathways. Recent research also explores its role in metabolic disorders and inflammation, highlighting its broader physiological relevance.
Overall, DHRS2 recombinant protein serves as a vital tool for dissecting its multifunctional roles in health and disease, offering potential avenues for drug development and biomarker discovery.
×
